- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.07. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Inhibrx expands credit facility to $500 million with Oxford | 3 | Investing.com | ||
| 15.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Inhibrx BLA for ozekibart accepted by FDA | 1 | Seeking Alpha | ||
| 15.06. | FDA akzeptiert Zulassungsantrag von Inhibrx für Medikament gegen seltenen Knochenkrebs | 3 | Investing.com Deutsch | ||
| 15.06. | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | 317 | PR Newswire | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | Stifel reiterates Inhibrx Biosciences stock rating on durability data | 1 | Investing.com | ||
| 02.06. | Inhibrx: Stifel bestätigt Kaufempfehlung nach überzeugenden Daten zur Wirkungsdauer | 2 | Investing.com Deutsch | ||
| 14.05. | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | 622 | PR Newswire | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| 11.05. | Inhibrx delivers 'differentiated' cancer drug data; Fractyl starts diabetes gene therapy trial | 4 | BioPharma Dive | ||
| 11.05. | Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data | 5 | FierceBiotech | ||
| 11.05. | Inhibrx reports interim phase 2 data for cancer drug trial | 2 | Investing.com | ||
| 11.05. | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | 418 | PR Newswire | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| 08.05. | Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset | 1 | Seeking Alpha | ||
| 22.04. | Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges | 1 | Benzinga.com | ||
| 22.04. | Stifel raises Inhibrx Biosciences price target on trial optimism | 2 | Investing.com | ||
| 22.04. | Stifel verdoppelt Kursziel für Inhibrx Biosciences aufgrund von Studienoptimismus | 2 | Investing.com Deutsch | ||
| 22.04. | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | 1.103 | AFX News | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 22.04. | Inhibrx cancer drug reportedly drawing interest of Merck and rivals | 3 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,07 | -0,10 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | -4,94 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | -27,16 % | Warum die Aktie von Monte Rosa Therapeutics heute abstürzt | ||
| EDGEWISE THERAPEUTICS | 38,430 | -6,54 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -5,92 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | +0,59 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | -3,05 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | -2,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | -2,74 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | +2,43 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -1,77 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +3,04 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,195 | +5,20 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
INHIBRX BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +3,21 (+4,05 %) liegt der Kurs bei 82,46 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.